KDM5D and prostate carcinoma: Having first identified that loss of the epigenetic factor KDM5D leads to more aggressive hormone‐sensitive prostate cancer in vitro and increased risk of relapse after treatment of localized disease, we endeavored to identify the pathways activated with the loss of KDM5D that lead to more rapid proliferation, and resistance to ADT and docetaxel [10, 29].